Shifting Paradigms: The Case of Autologous Reconstitution after an Upfront Matched Unrelated Hematopoietic Cell Transplantation for Severe Acquired Aplastic Anemia in a Child
- PMID: 38003941
- PMCID: PMC10672784
- DOI: 10.3390/medicina59111890
Shifting Paradigms: The Case of Autologous Reconstitution after an Upfront Matched Unrelated Hematopoietic Cell Transplantation for Severe Acquired Aplastic Anemia in a Child
Abstract
During the last few years, the therapeutic landscape of idiopathic aplastic anemia (IAA) has been profoundly revolutionized by the increased use of alternative transplant procedures, such that today hematopoietic cell transplantation (HCT) from a matched unrelated donor (MUD) has been suggested as a possible first line strategy in pediatric patients with severe IAA, in the absence of a matched related donor. However, in this particular context, outcomes and early and long-term toxicities remain to be determined, as compared to non-transplant procedures. While prospective trials are ongoing, we report here the case of a 12-year-old boy with IAA, receiving an upfront bone marrow HCT from a MUD, who experienced early graft rejection associated with autologous hematological recovery, which could induce remission of his hemopathy. This case offers the opportunity to discuss the challenges associated with these new transplant paradigms and provides a brief review of the literature regarding the issue of autologous recoveries after allogeneic HCT in IAA.
Keywords: MUD HCT; autologous reconstitution; graft failure; severe aplastic anemia.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation.Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):225-33. doi: 10.1007/s00005-012-0174-1. Epub 2012 Apr 17. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22527354
-
The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia.Biol Blood Marrow Transplant. 2019 Sep;25(9):e277-e284. doi: 10.1016/j.bbmt.2019.05.012. Epub 2019 May 24. Biol Blood Marrow Transplant. 2019. PMID: 31129354 Review.
-
Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.Transplant Cell Ther. 2022 Feb;28(2):105.e1-105.e7. doi: 10.1016/j.jtct.2021.10.006. Epub 2021 Oct 11. Transplant Cell Ther. 2022. PMID: 34649020
-
Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.Haematologica. 2014 Oct;99(10):1574-81. doi: 10.3324/haematol.2014.106096. Epub 2014 Aug 1. Haematologica. 2014. PMID: 25085353 Free PMC article.
-
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.Blood Rev. 2021 May;47:100772. doi: 10.1016/j.blre.2020.100772. Epub 2020 Oct 31. Blood Rev. 2021. PMID: 33187812 Review.
References
-
- Peffault de Latour R., Kulasekararaj A., Iacobelli S., Terwel S.R., Cook R., Griffin M., Constantijn J.M., Halkes M.D., Christian Recher M.D., Fiorenza Barraco M.D., et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N. Engl. J. Med. 2022;386:11–23. doi: 10.1056/NEJMoa2109965. - DOI - PubMed
-
- Kulasekararaj A.G., Hill A., Rottinghaus S.T., Langemeijer S., Wells R., Gonzalez-Fernandez F.A., Gaya A., Lee J.W., Gutierrez E.O., Piatek C.I., et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study. Blood. 2019;133:540–549. doi: 10.1182/blood-2018-09-876805. - DOI - PMC - PubMed
-
- Lee J.W., Sicre de Fontbrune F., Wong Lee Lee L., Pessoa V., Gualandro S., Füreder W., Ptushkin V., Rottinghaus S.T., Volles L., Shafner L., et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2019;133:530–539. doi: 10.1182/blood-2018-09-876136. - DOI - PMC - PubMed
-
- Risitano A.M., Röth A., Soret J., Frieri C., de Fontbrune F.S., Marano L., Alashkar F., Benajiba L., Marotta S., Rozenberg I., et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: An open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8:e344–e354. doi: 10.1016/S2352-3026(21)00028-4. - DOI - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical